Correction to: Nature Communications https://doi.org/10.1038/s41467-021-27799-z, published online 24 January 2022.
The original version of this Article contained errors in References 1, 33 and 77.
Ref. 1 was incorrectly given with incomplete bibliographical information as: ‘Jackson, L. A. et al. An mRNA Vaccine against SARS-CoV-2 – Preliminary Report. N. Engl. J. Med. (2020)’. The correct form of Ref. 1 is: ‘Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N. Engl. J. Med. 383, 1920–1931 (2020)’.
Ref. 33 was incorrectly given with incomplete patent information as: ‘Bradbury, A. R. M., Erasmus, M. F. & Teixeira, A. (ed. USPTO) (Specifica Inc, US; 2020)’. The correct form of Ref. 33 is: ‘Bradbury, A. R. M., Erasmus, M. F. & Teixeira, A. A. R. US patent 10,954,508 (2021)’.
Ref. 77, which was given as: ‘77. Kreye, J. et al. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. Cell 183, 1058–1069 e1019 (2020).’, was a duplication of Ref. 48. In the correct version, the duplicate reference is removed and all other references are renumbered accordingly.
In addition, the original version of this Article contained an error in the fourth sentence of the Discussion, which incorrectly read ‘Presently, 86 vaccines against 18 different organisms (including strains) are approved for use in the US’ The correct version replaces this sentence with ‘Presently, 103 vaccines against 32 different organisms (including strains) are approved for use in the US’.
This has been corrected in both the PDF and HTML versions of the Article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ferrara, F., Erasmus, M.F., D’Angelo, S. et al. Author Correction: A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies. Nat Commun 13, 2097 (2022). https://doi.org/10.1038/s41467-022-29876-3
Published:
DOI: https://doi.org/10.1038/s41467-022-29876-3
This article is cited by
-
Insights into next generation sequencing guided antibody selection strategies
Scientific Reports (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
